A Phase 2 Clinical Study in Children With HeFH Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing - Trial NCT05694260
Access comprehensive clinical trial information for NCT05694260 through Pure Global AI's free database. This Phase 2 trial is sponsored by Esperion Therapeutics, Inc. and is currently Recruiting. The study focuses on Hypercholesterolemia. Target enrollment is 54 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Esperion Therapeutics, Inc.
Timeline & Enrollment
Phase 2
Jan 12, 2023
May 24, 2024
Primary Outcome
Observed pharmacokinetics - trough plasma concentration of ETC-1002,Model-based pharmacokinetics - AUC, ss,Model-based pharmacokinetics - Cavg, ss,Model-based pharmacokinetics - Cmax, ss
Summary
Multiple-dose study to measure PK, PD and safety of bempedoic acid in pediatric patients 6 to
 17 years of age with HeFH.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05694260
Non-Device Trial